NCT01964924: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 331 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01964924 |
|---|---|
| Title | A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 2, 2013 |
| Completion date | Jan. 20, 2017 |
| Required reporting date | Jan. 20, 2018, midnight |
| Actual reporting date | Dec. 17, 2018 |
| Date last checked at ClinicalTrials.gov | Nov. 14, 2025 |
| Days late | 331 |